Agence France-Presse: New weapons drawn in global TB fight
“From a revolutionary way of testing children for tuberculosis to a cure for a previously untreatable strain, scientists from across the globe launched a fresh broadside Thursday against the world’s deadliest infectious disease. … More than 4,000 experts on lung health are gathering this week in The Hague and on Thursday they unveiled several new weapons in the battle against tuberculosis. One potential game changer is a new method of testing children under five for the disease…” (10/25).

CNN: New vaccine and drug combo offer hope against world’s biggest infectious killer
“…[A] special trial, beaming the number ’54,’ woke [researchers] from resignation and gave the first signs of hope in years. The number stood for a percentage — 54 percent. It meant that a tuberculosis vaccine that crosses a coveted efficacy threshold may soon be possible — and effective. The vaccine, known as M72/AS01E, has been developed by GlaxoSmithKline and is the first vaccine of many recent attempts to show more than 50 percent protection against people developing TB, as published in the New England Journal of Medicine…” (Senthilingam, 10/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.